BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 29606052)

  • 1. Medical management of meningioma in the era of precision medicine.
    Gupta S; Bi WL; Dunn IF
    Neurosurg Focus; 2018 Apr; 44(4):E3. PubMed ID: 29606052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The Potential of Personalized/Precision Medicine for Meningiomas].
    Yamaguchi S; Fujimura M
    No Shinkei Geka; 2022 Jan; 50(1):132-140. PubMed ID: 35169093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights into meningioma: from genetics to trials.
    Vranic A; Peyre M; Kalamarides M
    Curr Opin Oncol; 2012 Nov; 24(6):660-5. PubMed ID: 22820412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A five year-old child with clear cell petro-clival meningioma: case report with clinical and histopathological long-term follow-up.
    Juratli TA; Geiger KD; Weigel P; von der Hagen M; Daubner D; Pinzer T; Hahn G; Schackert G; Kirsch M
    Childs Nerv Syst; 2015 Nov; 31(11):2193-8. PubMed ID: 26077595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innovative treatments for meningiomas.
    Graillon T; Tabouret E; Salgues B; Horowitz T; Padovani L; Appay R; Farah K; Dufour H; RĂ©gis J; Guedj E; Barlier A; Chinot O
    Rev Neurol (Paris); 2023 Jun; 179(5):449-463. PubMed ID: 36959063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evidence-based treatment algorithm for the management of WHO Grade II and III meningiomas.
    Sun SQ; Hawasli AH; Huang J; Chicoine MR; Kim AH
    Neurosurg Focus; 2015 Mar; 38(3):E3. PubMed ID: 25727225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic landscape of intracranial meningiomas.
    Bi WL; Abedalthagafi M; Horowitz P; Agarwalla PK; Mei Y; Aizer AA; Brewster R; Dunn GP; Al-Mefty O; Alexander BM; Santagata S; Beroukhim R; Dunn IF
    J Neurosurg; 2016 Sep; 125(3):525-35. PubMed ID: 26771848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments.
    Choy W; Kim W; Nagasawa D; Stramotas S; Yew A; Gopen Q; Parsa AT; Yang I
    Neurosurg Focus; 2011 May; 30(5):E6. PubMed ID: 21529177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical therapies for meningiomas.
    Wen PY; Quant E; Drappatz J; Beroukhim R; Norden AD
    J Neurooncol; 2010 Sep; 99(3):365-78. PubMed ID: 20820875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical Management of Meningiomas: Current Status, Failed Treatments, and Promising Horizons.
    Karsy M; Guan J; Cohen A; Colman H; Jensen RL
    Neurosurg Clin N Am; 2016 Apr; 27(2):249-60. PubMed ID: 27012389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene therapy for meningioma: improved gene delivery with targeted adenoviruses.
    Dirven CM; Grill J; Lamfers ML; Van der Valk P; Leonhart AM; Van Beusechem VW; Haisma HJ; Pinedo HM; Curiel DT; Vandertop WP; Gerritsen WR
    J Neurosurg; 2002 Aug; 97(2):441-9. PubMed ID: 12186474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracranial meningiomas, the VEGF-A pathway, and peritumoral brain oedema.
    Nassehi D
    Dan Med J; 2013 Apr; 60(4):B4626. PubMed ID: 23651727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current treatment options for meningioma.
    Apra C; Peyre M; Kalamarides M
    Expert Rev Neurother; 2018 Mar; 18(3):241-249. PubMed ID: 29338455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinicopathological analysis of receptor tyrosine kinases in meningiomas: the expression of VEGFR-2 in meningioma was associated with a higher WHO grade and shorter progression-free survival.
    Nakada S; Sasagawa Y; Tachibana O; Iizuka H; Kurose N; Shioya A; Guo X; Yamada S; Nojima T
    Brain Tumor Pathol; 2019 Jan; 36(1):7-13. PubMed ID: 30519894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas.
    Sioka C; Kyritsis AP
    J Neurooncol; 2009 Mar; 92(1):1-6. PubMed ID: 19023520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma.
    Aizer AA; Abedalthagafi M; Bi WL; Horvath MC; Arvold ND; Al-Mefty O; Lee EQ; Nayak L; Rinne ML; Norden AD; Reardon DA; Wen PY; Ligon KL; Ligon AH; Beroukhim R; Dunn IF; Santagata S; Alexander BM
    Neuro Oncol; 2016 Feb; 18(2):269-74. PubMed ID: 26323607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human meningiomas co-express platelet-derived growth factor (PDGF) and PDGF-receptor genes and their protein products.
    Maxwell M; Galanopoulos T; Hedley-Whyte ET; Black PM; Antoniades HN
    Int J Cancer; 1990 Jul; 46(1):16-21. PubMed ID: 2163990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A narrative review of targeted therapy in meningioma, pituitary adenoma, and craniopharyngioma of the skull base.
    Martinez NL; Khanna O; Farrell CJ
    Chin Clin Oncol; 2020 Dec; 9(6):75. PubMed ID: 32819111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel therapies for meningiomas.
    Wen PY; Drappatz J
    Expert Rev Neurother; 2006 Oct; 6(10):1447-64. PubMed ID: 17078786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clear cell meningiomas: three case reports with genetic characterization and review of the literature.
    Ohba S; Sasaki H; Kimura T; Ikeda E; Kawase T
    Neurosurgery; 2010 Sep; 67(3):E870-1; discussion E871. PubMed ID: 20683214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.